Skip to search formSkip to main contentSkip to account menu

R207910

Known as: R 207910, TMC 207, TMC-207 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

bedaquiline

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Recent Advances in the Development of Anti-tuberculosis Drugs Acting on Multidrug-Resistant Strains: A review
Despite over a century of drug development research, tuberculosis remains a major public health problem with a leading cause of… 
2015
2015
Targeting Dormant Tuberculosis Bacilli: Results for Molecules with a Novel Pyrimidone Scaffold
Our inability to completely control TB has been due in part to the presence of dormant mycobacteria. This also renders drug… 
2014
2014
Initial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India.
Drug-resistant tuberculosis (DR-TB) is a major problem both in India and worldwide. Newer drugs such as TMC-207 (bedaquiline) may… 
Review
2014
Review
2014
Tuberculosis: current treatment, diagnostics, and newer antitubercular agents in clinical trials.
Tuberculosis (TB), a dreadful disease is one of the most important health problems worldwide, and is responsible for… 
2012
2012
Safety , Tolerability , and Pharmacokinetic Interactions of the Antituberculous Agent TMC 207 ( Bedaquiline ) With Efavirenz in Healthy Volunteers : AIDS Clinical Trials Group Study A 5267
Methods: This was a phase 1 pharmacokinetic drug interaction trial. Each healthy volunteer received two 400 mg doses of… 
Highly Cited
2010
Highly Cited
2010
Catalytic asymmetric synthesis of R207910.
The first asymmetric synthesis of a very promising antituberculosis drug candidate, R207910, was achieved by developing two novel… 
2009
2009
Unorthodox approach to the development of a new antituberculosis therapy.
The development of TMC207 represents an important advance in the chemotherapy of tuberculosis. It is perhaps most amazing because… 
2009
2009
Les nouveaux antituberculeux
2007
2007
The open book of infectious diseases
New classes of chemical compounds along with more efficient methods to identify drug targets have produced exciting developments… 
2006
2006
Conformational Analysis of R207910, a New Drug Candidate for the Treatment of Tuberculosis, by a Combined NMR and Molecular Modeling Approach
R207910 is an enantiomeric compound from a new class of antimycobacterial agents, the diarylquinolines [Science; 307:223 (2005… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)